The Present and Future of Yellow Fever Vaccines

Clairissa A. Hansen; Alan D. T. Barrett

doi:10.3390/ph14090891

journal article Open Access Sep 01, 2021

The Present and Future of Yellow Fever Vaccines

Clairissa A. Hansen

Alan D. T. Barrett

Pharmaceuticals Vol. 14 No. 9 pp. 891 · MDPI AG

View at Publisher Save 10.3390/ph14090891

Abstract

The disease yellow fever (YF) is prevented by a live-attenuated vaccine, termed 17D, which has been in use since the 1930s. One dose of the vaccine is thought to give lifelong (35+ years) protective immunity, and neutralizing antibodies are the correlate of protection. Despite being a vaccine-preventable disease, YF remains a major public health burden, causing an estimated 109,000 severe infections and 51,000 deaths annually. There are issues of supply and demand for the vaccine, and outbreaks in 2016 and 2018 resulted in fractional dosing of the vaccine to meet demand. The World Health Organization (WHO) has established the “Eliminate Yellow Fever Epidemics” (EYE) initiative to reduce the burden of YF over the next 10 years. As with most vaccines, the WHO has recommendations to assure the quality, safety, and efficacy of the YF vaccine. These require the use of live 17D vaccine only produced in embryonated chicken eggs, and safety evaluated in non-human primates only. Thus, any second-generation vaccines would require modification of WHO recommendations if they were to be used in endemic countries. There are multiple second-generation YF vaccine candidates in various stages of development that must be shown to be non-inferior to the current 17D vaccine in terms of safety and immunogenicity to progress through clinical trials to potential licensing. The historic 17D vaccine continues to shape the global vaccine landscape in its use in the generation of multiple licensed recombinant chimeric live vaccines and vaccine candidates, in which its structural protein genes are replaced with those of other viruses, such as dengue and Japanese encephalitis. There is no doubt that the YF 17D live-attenuated vaccine will continue to play a role in the development of new vaccines for YF, as well as potentially for many other pathogens.

Topics

No keywords indexed for this article. Browse by subject →

References

131

[1]

(2021, June 11). Transmission of Yellow Fever Virus, Available online: https://www.cdc.gov/yellowfever/transmission/index.html.

[2]

Jentes "The revised global yellow fever risk map and recommendations for vaccination, 2010: Consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever" Lancet Infect. Dis. (2011) 10.1016/s1473-3099(11)70147-5

[3]

Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2013). 38-Yellow fever vaccine. Vaccines, W.B. Saunders. [6th ed.].

[4]

Beck "Current status and future prospects of yellow fever vaccines" Expert Rev. Vaccines (2015) 10.1586/14760584.2015.1083430

[5]

Barrett "Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease" Vaccine (2017) 10.1016/j.vaccine.2017.03.032

[6]

Barrett "The reemergence of yellow fever" Science (2018) 10.1126/science.aau8225

[7]

Gaythorpe "The global burden of yellow fever" Elife (2021) 10.7554/elife.64670

[8]

Hughes "Phylogeny of Yellow Fever Virus, Uganda, 2016" Emerg. Infect. Dis. (2018) 10.3201/eid2408.180588

[9]

Abdullahi "The interplay between environmental factors, vector competence and vaccine immunodynamics as possible explanation of the 2019 yellow fever re-emergence in Nigeria" New Microbes New Infect. (2021) 10.1016/j.nmni.2021.100858

[10]

WHO (2018). Epidemiological Update: Yellow Fever. 20 March 2018 Pan American Health Organization, World Health Organization.

[11]

World Health Organization (2018). A Global Strategy to Eliminate Yellow Fever Epidemics 2017–2026, World Health Organization.

[12]

Davis "Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes" Viral. Immunol. (2020) 10.1089/vim.2019.0107

[13]

Staples, J.E., Monath, T.P., Gershman, M.D., and Barrett, A.D. (2018). Yellow fever vaccines. Plotkin’s Vaccines, Elsevier. 10.1016/b978-0-323-35761-6.00063-8

[14]

Van den Elsen, K., Quek, J.P., and Luo, D. (2021). Molecular Insights into the Flavivirus Replication Complex. Viruses, 13. 10.3390/v13060956

[15]

Mazzon "Pathogenesis of flavivirus infections: Using and abusing the host cell" Cell Host Microbe (2009) 10.1016/j.chom.2009.04.001

[16]

Lee "Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry" J. Virol. (2000) 10.1128/jvi.74.19.8867-8875.2000

[17]

Meertens "Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses" mBio (2016) 10.1128/mbio.01956-15

[18]

Hu "The key amino acids of E protein involved in early flavivirus infection: Viral entry" Virol. J. (2021) 10.1186/s12985-021-01611-2

[19]

Theiler "The Effect of Prolonged Cultivation In Vitro Upon the Pathogenicity of Yellow Fever Virus" J. Exp. Med. (1937) 10.1084/jem.65.6.767

[20]

McElroy "Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3’non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut" Am. J. Trop. Med. Hyg. (2006) 10.4269/ajtmh.2006.75.1158

[21]

Beck "Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing" J. Infect. Dis. (2014) 10.1093/infdis/jit546

[22]

Tangy "Yellow fever vaccine attenuation revealed: Loss of diversity" J. Infect. Dis. (2014) 10.1093/infdis/jit551

[23]

Pugachev "New developments in flavivirus vaccines with special attention to yellow fever" Curr. Opin. Infect. Dis. (2005) 10.1097/01.qco.0000178823.28585.ad

[24]

Beck "Analysis By Deep Sequencing of Discontinued Neurotropic Yellow Fever Vaccine Strains" Sci. Rep. (2018) 10.1038/s41598-018-31085-2

[25]

Soares "Testing the genomic stability of the Brazilian yellow fever vaccine strain using next-generation sequencing data" Interface Focus (2021) 10.1098/rsfs.2020.0063

[26]

Salmona "Molecular characterization of the 17D-204 yellow fever vaccine" Vaccine (2015) 10.1016/j.vaccine.2015.08.055

[27]

Victoria "Viral nucleic acids in live-attenuated vaccines: Detection of minority variants and an adventitious virus" J. Virol. (2010) 10.1128/jvi.02690-09

[28]

Pestana "Sanger-based sequencing technology for yellow fever vaccine genetic quality control" J. Virol. Methods (2018) 10.1016/j.jviromet.2018.07.006

[29]

World Health Organization (1945). Standards for the Manufacture and Control of Yellow Fever Vaccine. World Health Organization Epidemiological Bulletin, World Health Organization.

[30]

WHO (2016). International Health Regulations (2005), World Health Organization.

[31]

WHO (2013). Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. Annex 5, Standardization, WHO.

[32]

Perraut "Stability-related studies on 17D yellow fever vaccine" Microbes Infect. (2000) 10.1016/s1286-4579(00)00288-4

[33]

Lang "Comparison of the immunogenicity and safety of two 17D yellow fever vaccines" Am. J. Trop. Med. Hyg. (1999) 10.4269/ajtmh.1999.60.1045

[34]

Sanchez "Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru" Am. J. Trop. Med. Hyg. (2005) 10.4269/ajtmh.2005.72.189

[35]

Kimathi "Immunogenicity and safety of fractional doses of yellow fever vaccines: A randomised, double-blind, non-inferiority trial" Lancet (2021) 10.1016/s0140-6736(20)32520-4

[36]

Mason "Yellow fever vaccine: Direct challenge of monkeys given graded doses of 17D vaccine" Appl. Microbiol. (1973) 10.1128/am.25.4.539-544.1973

[37]

Julander "Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model" Vaccine (2011) 10.1016/j.vaccine.2011.06.034

[38]

WHO (2003). Weekly Epidemiological Record: Yellow Fever Vaccine, World Health Organization.

[39]

Wieten, R.W., Jonker, E.F., van Leeuwen, E.M., Remmerswaal, E.B., Ten Berge, I.J., de Visser, A.W., van Genderen, P.J., Goorhuis, A., Visser, L.G., and Grobusch, M.P. (2016). A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS ONE, 11. 10.1371/journal.pone.0149871

[40]

Staples "Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection" NPJ Vaccines (2020) 10.1038/s41541-020-0205-6

[41]

Gotuzzo "Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years" Am. J. Trop. Med. Hyg. (2013) 10.4269/ajtmh.13-0264

[42]

Casey "Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak-Final Report" N. Engl. J. Med. (2019) 10.1056/nejmoa1710430

[43]

Hepburn "Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine" Vaccine (2006) 10.1016/j.vaccine.2005.12.055

[44]

Kongsgaard "Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination" Sci. Rep. (2017) 10.1038/s41598-017-00798-1

[45]

ACIP (2015). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Yellow Fever Vaccine Booster Doses.

[46]

"Duration of post-vaccination humoral immunity against yellow fever in children" Vaccine (2019) 10.1016/j.vaccine.2019.09.051

[47]

Sanofi Pasteur Inc (2016). Yellow Fever Vaccine: YF-VAX® Product Information, Sanofi Pasteur Inc.

[48]

Veit "Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients" Clin. Infect. Dis. (2009) 10.1086/597006

[49]

Veit "Study, S.H.C., Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule" Clin. Infect. Dis. (2018) 10.1093/cid/cix960

[50]

Martin "Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: A systematic review" Clin. Microbiol. Infect. (2021) 10.1016/j.cmi.2021.03.004

Showing 50 of 131 references

Cited By

61

The Yellow Fever Vaccine Journey: Milestones and Future Directions

Shriyansh Srivastava, Nandani Jayaswal · 2026

Vaccines

Effectiveness of the Local Additional Risk Minimisation Measures for Yellow Fever Vaccine in the United Kingdom: A Survey of Healthcare Professionals and Vaccinees

Leila Karimi, Artis Luguzis · 2026

Pharmacoepidemiology and Drug Safet...

Preventative Vaccination of Nonhuman Primates

Remco A. Nederlof, Sanna Sainmaa · 2025

Journal of Zoological and Botanical...

YF17D‐based vaccines – standing on the shoulders of a giant

Lorena Sanchez‐Felipe, Yeranddy A. Alpizar · 2024

European Journal of Immunology

Yellow fever vaccine coverage and associated factors among under-five children in Kenya: Data from Kenyan Demographic and Health Survey 2022

Mohammed Seid Ali, Enyew Getaneh Mekonen · 2024

Human Vaccines & Immunotherapeu...

Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model

Ian J. Amanna, Archana Thomas · 2024

Cell Reports Medicine

YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge

Viktor Lemmens, Lara Kelchtermans · 2023

npj Vaccines

Metrics

61

Citations

131

References

Details

Published: Sep 01, 2021
Vol/Issue: 14(9)
Pages: 891
License: View

Authors

C

Clairissa A. Hansen

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-4036, USA

A

Alan D. T. Barrett

Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-4036, USA; Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555-4036, USA

Cite This Article

Clairissa A. Hansen, Alan D. T. Barrett (2021). The Present and Future of Yellow Fever Vaccines. Pharmaceuticals, 14(9), 891. https://doi.org/10.3390/ph14090891

The Present and Future of Yellow Fever Vaccines

You May Also Like